Organogenesis Holdings Inc.

During the three months ended September 30, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.

On October 31, 2025, the Company entered into the October 2025 Amendment to the 2021 Credit Agreement. The October 2025 Amendment (a) reduced the Revolving Facility from $125,000,000 to $75,000,000, (b) removed the Consolidated Fixed Charge Coverage Ratio covenant, (c) added a minimum Consolidated Interest Coverage Ratio covenant that requires consolidated EBITDA for any period of four consecutive fiscal quarters to equal or exceed 300% of consolidated cash interest expense for such period and (iv) added a Consolidated Capital Expenditures covenant, which requires consolidated capital expenditures to be less than $50,000,000 during any 12-month period during which outstanding loans under the Revolving Facility exceed $50,000,000. The Company paid the lenders an amendment fee of $112,500 in connection with the October 2025 Amendment.

The foregoing description of the October 2025 Amendment is not complete and is qualified in its entirety by reference to the October 2025 Amendment, which is attached to this Current Report on Form 10-Q as Exhibit 10.2 and incorporated herein by reference.